Natalie Callander | Department of ...

Dr. Natalie Callander

Claim this profile

University of Wisconsin Hospitals and Clinics

Expert in Multiple Myeloma
Studies Childhood Blood Disease
11 reported clinical trials
20 drugs studied

Area of expertise

1

Multiple Myeloma

Global Leader

Natalie Callander has run 11 trials for Multiple Myeloma. Some of their research focus areas include:

Stage III
Stage IV
HBcAb positive
2

Childhood Blood Disease

Natalie Callander has run 1 trial for Childhood Blood Disease.

Affiliated Hospitals

Image of trial facility.

University Of Wisconsin School Of Medicine And Public Health

Image of trial facility.

University Of Wisconsin Hospitals And Clinics

Clinical Trials Natalie Callander is currently running

Image of trial facility.

Iberdomide Combo

for Multiple Myeloma

Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administration, and compelling single agent activity even in heavily pretreated MM, iberdomide is likely amenable to long term therapy in patients with high-risk of relapse/progression identified by the persistence of MRD(+). The investigators intend to develop combination(s) of iberdomide with other agents with complementary mechanism of action in the consolidation setting post AHCT in order to achieve and sustain MRD (-).

Recruiting

3 awards

Phase 1 & 2

14 criteria

Image of trial facility.

Lenalidomide + Dexamethasone +/- Daratumumab

for Multiple Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

Recruiting

2 awards

Phase 3

12 criteria

More about Natalie Callander

Clinical Trial Related

3 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Natalie Callander has experience with

  • Lenalidomide
  • Dexamethasone
  • Daratumumab
  • Bortezomib
  • Carfilzomib
  • Belantamab Mafodotin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Natalie Callander specialize in?

Is Natalie Callander currently recruiting for clinical trials?

Are there any treatments that Natalie Callander has studied deeply?

What is the best way to schedule an appointment with Natalie Callander?

What is the office address of Natalie Callander?

Is there any support for travel costs?